Previous 10 | Next 10 |
Applied Molecular Transport (AMTI) commenced an underwritten public offering of 2.5M shares; underwriters granted 30-day option to purchase up to an additional 375K shares.Offer size, terms not yet disclosed. For further details see: Applied Molecular Transport proposes 2.5M ...
SOUTH SAN FRANCISCO, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of 2,500,000 shares of its common stock. All of the shares...
Applied Molecular Transport (AMTI): FY GAAP EPS of -$2.91 beats by $0.38.As of December 31, 2020, cash, cash equivalents, and investments were $129.9 million.Press Release For further details see: Applied Molecular Transport EPS beats by $0.38
Successfully initiated four planned Phase 2 trials for oral AMT-101 with enrollment ongoing Company on track to announce oral AMT-101 top-line data readouts from the four Phase 2 trials from its comprehensive clinical program, in multiple ulcerative colitis populations and rheum...
SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during th...
Applied Molecular Transport (AMTI) announces that the first patient has been dosed in its Phase 1a clinical trial of oral AMT-126, a novel, gastrointestinal ((GI))-selective oral fusion of human interleukin-22 ((hIL-22)).The company expects complete data from its oral AMT-126 Phase 1a/b ...
Company expands pipeline with second clinical program, AMT-126, an oral IL-22 fusion biologic therapy for diseases associated with intestinal epithelial barrier defects IL-22 deficiency implicated in broad range of gastrointestinal-focused and peripheral diseases ranging from ul...
The following slide deck was published by Applied Molecular Transport Inc. in conjunction with this event. For further details see: Applied Molecular Transport (AMTI) Investor Presentation - Slideshow
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the...
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has appointed Douglas Rich as Chief Technical Officer. In his new role, Douglas will assume leadership re...
News, Short Squeeze, Breakout and More Instantly...
Applied Molecular Transport Inc. Company Name:
AMTI Stock Symbol:
NASDAQ Market:
Applied Molecular Transport Inc. Website:
Combined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations Cyclo ...
Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceut...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...